Restricted accessLetterFirst published online 2024-8
LCP-Tacrolimus Requires a Similar Empiric Dose Adjustment to Immediate-Release Tacrolimus When Given Concomitantly With Letermovir for Cytomegalovirus Primary Prophylaxis
WangYHChenDHartmannGChoCRMenzelK.PBPK modeling strategy for predicting complex drug interactions of letermovir as a perpetrator in support of product labeling. Clin Pharmacol Ther. 2019;105(2):515-523. doi:10.1002/cpt.1120
WinsteadRJKumarDBrownA, et al. Letermovir prophylaxis in solid organ transplant—assessing CMV breakthrough and tacrolimus drug interaction. Transpl Infect Dis. 2021;23(4):e13570. doi:10.1111/tid.13570
4.
JorgensonMRDescourouezJLGargN, et al. The addition of adjunctive letermovir to valganciclovir for refractory cytomegalovirus viremia in kidney transplant recipients. Transpl Infect Dis. 2021;23(4):e13693. doi:10.1111/tid.13693
TremblaySNigroVWeinbergJWoodleESAllowayRR.A steady-state head-to-head pharmacokinetic comparison of all FK-506 (tacrolimus) formulations (ASTCOFF): an open-label, prospective, randomized, two-arm, three-period crossover study. Am J Transplant. 2017;17(2):432-442. doi:10.1111/ajt.13935
7.
LimayeAPBuddeKHumarA, et al. Letermovir vs valganciclovir for prophylaxis of cytomegalovirus in high-risk kidney transplant recipients: a randomized clinical trial. JAMA. 2023;330(1):33-42. doi:10.1001/jama.2023.9106
8.
OttCHuppertzAFoersterK, et al. Assessment of the effect of drug formulation on the extent of the pharmacokinetic interaction between voriconazole and tacrolimus. Nephrol Dial Transplant. 2018;33:i597-i598.
